sloan kettering cancer

(Wake Forest University Baptist Medical Center) A study of almost 1,500 kidney cancer patients treated at Memorial Sloan Kettering Cancer Center suggests that surgery to spare as much kidney tissue as possible may improve overall survival in patients who also have reduced kidney function at the time their cancer is diagnosed.

The finding is significant because both kidney cancer and decreased kidney function appear to be increasing.

(Memorial Sloan-Kettering Cancer Center) New data from a randomized, controlled trial found that acupuncture provided significant reductions in pain, dysfunction, and dry mouth in head and neck cancer patients after neck dissection.

(Memorial Sloan-Kettering Cancer Center) New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments.

Researchers at Dana-Farber Cancer Institute and Memorial Sloan-Kettering Cancer Center have developed a new algorithm for ranking abnormal genes according to their likelihood of contributing to a cancer.

They also show that a gene identified by the algorithm as a likely restrainer of tumor growth does indeed play that role in a common type of brain cancer, and is not a mere "bystander" to another restrainer gene.

A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity.

An international group of investigators led by scientists at Memorial Sloan-Kettering Cancer Center and the National Cancer Institute has identified a new genetic marker of risk for breast cancer.

Women with this DNA variation are at a 1.4 times greater risk of developing breast cancer compared to those without the variation.

The findings are to be published online on March 3, 2008 in the journal Proceedings of the National Academy of Sciences.

A new study led by researchers at Memorial Sloan-Kettering Cancer Center reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.

The protein, called AML1, plays a critical role in the development of the blood system and in the production of platelets and immune cells.

The findings are published in the March 1, 2008, issue of Genes & Development.